{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.55","upperLimit":"9.66","value":"6.93"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"DOR was defined as the time from the date of the first response (CR or PR), until the date of progressive disease (PD) or death from any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg AIBW administered IV on Day 1 of every 3-week cycle (Q3W).","id":"OG000","title":"Mirvetuximab Soravtansine"}],"paramType":"MEDIAN","populationDescription":"All participants that showed a CR or PR according to RECIST 1.1 were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to approximately 15 months","title":"Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1","type":"SECONDARY","unitOfMeasure":"months"}